CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that, in response to a letter from the company to the Nasdaq Stock Market reporting an inadvertent stock option grant to a member of its audit committee, Nasdaq notified the company on June 26, 2007 that it had been temporarily out of compliance with the audit committee independence listing requirement set forth in Nasdaq Marketplace Rule 4350(d)(2). The notice from Nasdaq also stated that the company had since regained compliance with Marketplace Rule 4350(d)(2) and did not require the company to make any changes to its audit committee composition.
